Thrivent Financial for Lutherans Lowers Stock Position in The Chemours Company $CC

Thrivent Financial for Lutherans lowered its position in shares of The Chemours Company (NYSE:CC) by 51.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 107,997 shares of the specialty chemicals company’s stock after selling 113,927 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Chemours were worth $1,711,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in CC. MTM Investment Management LLC bought a new stake in Chemours in the second quarter valued at approximately $27,000. Evelyn Partners Asset Management Ltd bought a new stake in Chemours during the 2nd quarter valued at approximately $37,000. FNY Investment Advisers LLC grew its stake in Chemours by 100.0% in the second quarter. FNY Investment Advisers LLC now owns 4,000 shares of the specialty chemicals company’s stock worth $45,000 after purchasing an additional 2,000 shares during the period. CWM LLC increased its stake in shares of Chemours by 34.7% in the 2nd quarter. CWM LLC now owns 4,290 shares of the specialty chemicals company’s stock worth $49,000 after acquiring an additional 1,104 shares in the last quarter. Finally, Itau Unibanco Holding S.A. increased its stake in shares of Chemours by 102.3% during the second quarter. Itau Unibanco Holding S.A. now owns 7,149 shares of the specialty chemicals company’s stock valued at $82,000 after purchasing an additional 3,615 shares in the last quarter. Institutional investors own 76.26% of the company’s stock.

Analyst Upgrades and Downgrades

CC has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. cut their price target on shares of Chemours from $15.00 to $13.00 and set a “neutral” rating on the stock in a report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d)” rating on shares of Chemours in a research note on Wednesday, January 21st. BMO Capital Markets restated an “outperform” rating and set a $20.00 target price on shares of Chemours in a research note on Monday, January 19th. Truist Financial upped their price objective on Chemours from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, January 21st. Finally, Mizuho dropped their price objective on shares of Chemours from $19.00 to $18.00 and set an “outperform” rating for the company in a report on Thursday, October 16th. Five equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $16.67.

Chemours Stock Down 2.9%

Chemours stock opened at $20.40 on Friday. The business has a fifty day moving average of $14.36 and a two-hundred day moving average of $14.13. The Chemours Company has a twelve month low of $9.13 and a twelve month high of $21.85. The company has a quick ratio of 0.88, a current ratio of 1.71 and a debt-to-equity ratio of 13.66. The firm has a market cap of $3.06 billion, a P/E ratio of -9.19 and a beta of 1.63.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.